Top Markets
Coin of the day
CH Biotech R&D Co., Ltd. CH Biotech R&D Co., Ltd.

CH Biotech R&D Co., Ltd.

6534
Rank in Stocks #16489
CH Biotech R&D Co., Ltd. is a company dedicated to the creation and worldwide... CH Biotech R&D Co., Ltd. is a company dedicated to the creation and worldwide supply of agricultural chemicals rooted in biotechnology. Their commercial footprint spans Taiwan, the United States, Canada, Australia, Brazil, Argentina, Uruguay, and Chile, in addition to other international markets. The firm's portfolio features plant growth regulators, fertilizers, and specialized biotechnology services. CH Biotech R&D Co., Ltd. was established in 2013 and is based in Nantou City, Taiwan.
Share Price
$2.89
Last synced: 2026-09-01
Market Cap
$291.69M
Change (1 day)
-1.09%
Change (1 year)
-24.57%
Country
TW
Trade CH Biotech R&D Co., Ltd. (6534)
P/E ratio for CH Biotech R&D Co., Ltd. (6534)
P/E ratio as of 2026 TTM: 0
According to CH Biotech R&D Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for CH Biotech R&D Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.